Kymera Therapeutics, Inc.
NASDAQ:KYMR
35.1 (USD) • At close March 12, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | 2019 Q3 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 7.394 | 3.741 | 25.65 | 10.287 | 47.885 | 4.728 | 16.513 | 9.466 | 16.139 | 9.551 | 11.514 | 9.622 | 15.275 | 20.336 | 18.519 | 18.702 | 12.785 | 14.533 | 3.288 | 3.428 | 1.833 | 0.95 |
| Cost of Revenue
| 0 | 2 | 1.9 | 1.5 | 0.865 | 0.9 | 0.9 | 0.9 | 0.818 | 43.877 | 0.7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 7.394 | 1.741 | 23.75 | 8.787 | 47.02 | 3.828 | 15.613 | 8.566 | 15.321 | -34.326 | 10.814 | 9.622 | 15.275 | 20.336 | 18.519 | 18.702 | 12.785 | 14.533 | 3.288 | 3.428 | 1.833 | 0.95 |
| Gross Profit Ratio
| 1 | 0.465 | 0.926 | 0.854 | 0.982 | 0.81 | 0.945 | 0.905 | 0.949 | -3.594 | 0.939 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Reseach & Development Expenses
| 71.817 | 60.41 | 57.302 | 48.819 | 52.97 | 48.117 | 45.767 | 42.227 | 43.133 | 43.877 | 41.293 | 35.944 | 37.53 | 38.306 | 35.22 | 25.962 | 20.392 | 15.778 | 13.819 | 12.116 | 11.086 | 11.31 |
| General & Administrative Expenses
| 16.332 | 15.455 | 17.373 | 14.374 | 14.227 | 14.12 | 14.129 | 12.565 | 11.637 | 10.556 | 11.031 | 10.611 | 11.74 | 10.667 | 8.029 | 5.909 | 5.175 | 6.838 | 3.661 | 2.559 | 2.53 | 1.501 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 16.332 | 15.455 | 17.373 | 14.374 | 14.227 | 14.12 | 14.129 | 12.565 | 11.637 | 10.556 | 11.031 | 10.611 | 11.74 | 10.667 | 8.029 | 5.909 | 5.175 | 6.838 | 3.661 | 2.559 | 2.53 | 1.501 |
| Other Expenses
| 0 | 0 | 0 | -47.319 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 88.149 | 75.865 | 74.675 | 61.693 | 67.197 | 62.237 | 59.896 | 54.792 | 54.77 | 54.433 | 52.324 | 46.555 | 49.27 | 48.973 | 43.249 | 31.871 | 25.567 | 22.616 | 17.48 | 14.675 | 13.616 | 12.811 |
| Operating Income
| -80.755 | -72.124 | -50.925 | -52.906 | -19.312 | -57.509 | -43.383 | -45.326 | -38.631 | -44.882 | -40.81 | -36.933 | -33.995 | -28.637 | -24.73 | -13.169 | -12.782 | -8.083 | -14.192 | -11.247 | -11.783 | -11.861 |
| Operating Income Ratio
| -10.922 | -19.279 | -1.985 | -5.143 | -0.403 | -12.163 | -2.627 | -4.788 | -2.394 | -4.699 | -3.544 | -3.838 | -2.226 | -1.408 | -1.335 | -0.704 | -1 | -0.556 | -4.316 | -3.281 | -6.428 | -12.485 |
| Total Other Income Expenses Net
| 10.003 | 9.637 | 8.863 | 4.349 | 4.944 | 4.642 | 4.584 | 4.398 | 3.766 | 1.88 | 0.553 | 0.249 | 0.094 | 0.055 | 0.07 | 0.094 | 0.097 | 0.097 | 0.203 | 0.315 | 0.27 | 0.441 |
| Income Before Tax
| -70.752 | -62.487 | -42.062 | -48.557 | -14.368 | -52.867 | -38.799 | -40.928 | -34.865 | -43.002 | -40.257 | -36.684 | -33.901 | -28.582 | -24.66 | -13.075 | -12.685 | -7.986 | -13.989 | -10.932 | -11.513 | -11.42 |
| Income Before Tax Ratio
| -9.569 | -16.703 | -1.64 | -4.72 | -0.3 | -11.182 | -2.35 | -4.324 | -2.16 | -4.502 | -3.496 | -3.813 | -2.219 | -1.405 | -1.332 | -0.699 | -0.992 | -0.55 | -4.255 | -3.189 | -6.281 | -12.021 |
| Income Tax Expense
| 0 | 0 | 0 | 0.039 | 4.996 | -0.895 | 4.632 | -4.343 | -0.818 | 1.916 | -0.553 | -0.249 | 0.051 | 0.125 | 0.098 | 0.118 | -0.373 | 0.125 | 0.228 | 0.349 | 0.3 | 0.445 |
| Net Income
| -70.752 | -62.487 | -42.062 | -48.557 | -14.368 | -52.867 | -38.799 | -36.585 | -34.047 | -43.002 | -39.704 | -36.435 | -33.901 | -28.582 | -24.66 | -13.075 | -12.685 | -7.986 | -13.989 | -10.932 | -11.513 | -11.42 |
| Net Income Ratio
| -9.569 | -16.703 | -1.64 | -4.72 | -0.3 | -11.182 | -2.35 | -3.865 | -2.11 | -4.502 | -3.448 | -3.787 | -2.219 | -1.405 | -1.332 | -0.699 | -0.992 | -0.55 | -4.255 | -3.189 | -6.281 | -12.021 |
| EPS
| -0.88 | -0.82 | -0.58 | -0.69 | -0.25 | -0.9 | -0.67 | -0.63 | -0.59 | -0.79 | -0.77 | -0.71 | -0.66 | -0.56 | -0.55 | -0.29 | -0.29 | -0.18 | -0.32 | -0.25 | -0.26 | -0.26 |
| EPS Diluted
| -0.88 | -0.82 | -0.58 | -0.69 | -0.25 | -0.9 | -0.67 | -0.63 | -0.59 | -0.79 | -0.77 | -0.71 | -0.66 | -0.56 | -0.55 | -0.29 | -0.29 | -0.18 | -0.32 | -0.25 | -0.26 | -0.26 |
| EBITDA
| -68.706 | -60.427 | -40.101 | -46.988 | -13.451 | -51.926 | -37.851 | -39.973 | -33.989 | -42.199 | -39.516 | -35.943 | -33.162 | -27.841 | -24.08 | -12.566 | -12.161 | -7.468 | -13.575 | -10.511 | -11.122 | -11.258 |
| EBITDA Ratio
| -9.292 | -16.153 | -1.911 | -4.997 | -0.28 | -12.163 | -2.292 | -4.318 | -2.157 | -4.418 | -3.432 | -3.737 | -2.216 | -1.369 | -1.3 | -0.672 | -0.99 | -0.514 | -4.129 | -3.066 | -6.068 | -11.851 |